FIELD OF THE INVENTION: The present invention primarily discloses novel processes for the preparation of amorphous Linagliptin in a suitable solvent/s using spray drying technique. BACKGROUND OF THE INVENTION: Linagliptin, namely 8-(3R)-3-aminopiperidinyl)-7-butyn-2-yl-3 -methyl-1 -(4- methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione or l-[(4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-l-yl)-8-(3-(R)-amino- piperidin-1-yl) xanthine, of formula I, is a long acting inhibitor of dipeptidylpeptidase-IV (DPP-IV) activity, at present under development for the treatment of type II diabetes mellitus. Its international non-proprietary name is Linagliptin [CAS number: 668270-12-0] which has the following chemical structure of formula I. Formula I US patent number 7,407,955 (US '955) discloses Linagliptin, related compounds and their pharmaceutical compositions. Further, it describes a process for the preparation of Linagliptin wherein tert-butyloxy carbonyl (Boc) protectedLinagliptin is deprotected using 5-6 M isopropanolic hydrochloric acid or equivalent acid, followed by purification using chromatography. The process disclosed in US '955 is schematically represented in scheme-1. UN DMF,rt, 86<£ o^ KXO_v DMF, n 77-88% 0 rA DTPEA Br » i) racemisation (R)- or (S)-3-Boc-